What the registry entry says

The first-in-human study of TRG-035, a humanised monoclonal antibody against USAG-1, is registered at a university hospital in Kyoto as a single ascending dose study in adult participants with a safety primary endpoint. The Kitano Hospital trial announcement of 3 May 2024 records the study plan after PMDA clearance, reported 25 March 2024. Read as a registry entry, it establishes three things: the intervention, the population (adults), and the question (tolerability). It does not establish, and was never designed to establish, that a tooth can be induced in a person.

What the sponsor disclosure adds

Toregem BioPharma’s financing disclosure of 19 May 2026 describes Phase I as complete and Phase II as in preparation. The company materials place the initial indication at severe congenital tooth agenesis, and the program received Japanese orphan drug designation for severe congenital partial anodontia in September 2025. What is not public: peer-reviewed human safety results, dose findings, or any evidence of tooth induction. “Phase I complete” is a statement about a safety step finishing. It is not a result, and it is not an efficacy claim, though it is frequently read as both.

What the mechanism paper established

The preclinical basis is Murashima-Suginami et al., Science Advances, 12 February 2021. Blocking USAG-1 relieved congenital tooth agenesis in mouse models, and a single dose produced whole, erupting teeth in mice and in ferrets. The paper reports field-selective BMP action: removing USAG-1 raises BMP signalling in tissue already attempting to form a tooth, and a tooth that would not have formed does. That is a rescue of a suppressed developmental programme, demonstrated in animals. Translation to controlled tooth formation in a human remains the open question the clinical programme has not yet addressed.

Where we differ from the coverage

Three divergences between the coverage and the record recur.

First, the population. Phase I is repeatedly reported as enrolling children aged 2 to 6. The registry says adults. Children with congenital anodontia are the planned Phase II population, which is exactly what a first-in-human sequence requires: tolerability in adults first, efficacy in the intended population later.

Second, the date. Coverage describes the antibody as regrowing teeth in adults by 2030. No filing, guidance, or trial schedule in the record supports a 2030 availability date. It is a developer projection, first stated before Phase I completed and since carried without attribution.

Third, the mechanism. The antibody is often described as blocking BMP and Wnt together. The 2021 paper reports field-selective BMP action; the Wnt half is an inference from earlier reviews, not a finding of the paper.

What would move this program

Two things would change the record materially: an efficacy endpoint in children with congenital anodontia, reported with its statistical plan rather than by press release; and a dated human image showing a tooth in a site that was radiographically empty before treatment. Until one of those exists, the honest summary is the one in the current pass: one antibody has been given to adults, and everything else is upstream of a person.

Provenance: every claim above traces to the registry record, the sponsor disclosures, or the 2021 primary paper, per our method at /method/.